Last updated on May 2018

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma


Brief description of study

To estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), as measured by overall response rate (ORR), according to central review.

Clinical Study Identifier: NCT02760498

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Administrator

City of Hope Hospital
Duarte, CA United States
1.45miles
  Connect »